Vancomycin's Limited Effectiveness Against MRSA in Pneumonia

Strategic Insights -

Researchers in the United States evaluated the effectiveness of vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in pneumonia, finding that even high doses of the antibiotic failed to achieve significant bactericidal activity against the bacteria. The study, published in Antimicrobial Agents and Chemotherapy, simulated various vancomycin exposures using an in vitro pharmacodynamic model and population-based mathematical modeling to determine the impact of epithelial lining fluid penetration on bacterial killing and resistance. The researchers concluded that vancomycin's effectiveness against MRSA in pneumonia is limited, and that high doses may not be sufficient to prevent the development of resistance.

Key Takeaways:

  • The extent of vancomycin penetration into epithelial lining fluid (ELF) has a significant impact on bacterial killing and resistance against MRSA in pneumonia.
  • High-dose vancomycin regimens according to American Thoracic Society/Infectious Diseases Society of America guidelines failed to achieve significant bactericidal activity against MRSA.
  • The researchers found that even at high vancomycin exposures, all regimens up to a free area under the concentration-time curve to minimum inhibitory concentration (fAUC(24)/MIC) ratio of 350 did not achieve bactericidal activity.
  • Resistant mutants amplified by suboptimal vancomycin exposure displayed reduced rates of autolysis at 72 hours.
  • The population-based mathematical modeling indicated that a resistant and susceptible subpopulation coexisted in the bacterial population.
  • The researchers concluded that vancomycin's effectiveness against MRSA in pneumonia is limited, and that high doses may not be sufficient to prevent the development of resistance.

Statistics:

  • The study used two agr-functional, group II MRSA clinical isolates obtained from patients with a bloodstream infection (MIC = 1.0 mg/liter).
  • Bacterial growth and death were well characterized by a Hill-type model (R-squared = 0.984).
  • The population pharmacodynamic model had a R-squared value of 0.965.
  • Vancomycin exposures were simulated at six different concentrations: 0, 70, 140, 210, 280, and 350.
  • The fAUC(24)/MIC ratio values ranged from 0 to 350.

Sources:

  • Harigaya, Y., et al. "Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia." Antimicrobial Agents and Chemotherapy 53.9 (2009): 3894-3901.
  • American Society Microbiology, 1752 N St. NW, Washington, DC 20036-2904, USA.